Chimerix, Inc.

Equities

CMRX

US16934W1062

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.06 USD +4.95% Intraday chart for Chimerix, Inc. +10.88% +10.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chimerix Appoints Marc D. Kozin to Board of Directors CI
Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (CMRX) CHIMERIX Reports Q4 Revenue $4,000, vs. Street Est of $70,000 MT
Chimerix Announces Board Changes CI
Chimerix Names Michelle LaSpaluto Finance Chief MT
Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer CI
Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer CI
Transcript : Chimerix, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (CMRX) CHIMERIX Posts Q3 Revenue $11,000, vs. Street Est of $90,000 MT
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery CI
Transcript : Chimerix, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Earnings Flash (CMRX) CHIMERIX Posts Q2 Revenue $26,000, vs. Street Est of $270,000 MT
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chimerix Names Michael Andriole as Chief Executive Officer MT
Chimerix, Inc. Announces CEO Changes, Effective on August 1, 2023 CI
Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023 CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Comp Value Index CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 3000 Index CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Completeness Index CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Value Index CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Index CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Index CI
Chart Chimerix, Inc.
More charts
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.06 USD
Average target price
7.333 USD
Spread / Average Target
+591.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Chimerix, Inc. - Nasdaq
  4. News Chimerix, Inc.
  5. Cowen Lowers Price Target for Chimerix to $10 From $18, Maintains Outperform Rating